This case-series study shows that the combination of anti–PD-1 monoclonal antibodies and anti-VEGF agents is tolerable in patients with R/M HNSCC and that the treatment exhibits antitumor potential despite the heavily pretreated status of many enrolled patients. Here, PDCD1 is linked to head and neck squamous cell carcinoma.